glp-1 hormones Formula Weight Loss Therapy Glp-1 Gastrointestinal

Medical writing and editorial support were provided by Katie Willetts, PhD, and Jane Francis of Oxford PharmaGenesis, Oxford, UK, sponsored by AstraZeneca

Now that name-brand medications are more widely available, the need for compounded versions is significantly reduced

The approval was supported by results from the SURMOUNT-OSA trial that revealed Zepbound led to a significant reduction in the apnea-hypopnea index at 52 weeks compared to placebo in individuals who were and were not receiving PAP therapy

Adults with obesity but without type 2 diabetes received either the maximum tolerated dose of tirzepatide or the maximum tolerated dose of semaglutide

This medication is truly unique because it acts as a dual agonist, meaning it targets two different hormone receptors in your body: Glucagon-Like Peptide-1 (GLP-1) and Glucose-Dependent Insulinotropic Polypeptide (GIP)

The WHO is calling for more innovation and wider access to effective diagnostic and therapeutic tools